Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Safeguarding America's Pharmaceuticals Act of 2013
Client: ENDO INTERNATIONAL · Firm: ENDO INTERNATIONAL
Issues relating to bioequivalence and related administrative procedures Issues relating to prescription drug abuse Issues relating to incentives for tamper-resistant formulations H.R. 486--Stop Tampering of Prescription Pills Act of 2013Issues relating to Medicare Part D rebates Issues relating to health information technology H.R. 1919 -- Safeguarding America's Pharmaceuticals Act of 2013
Safeguarding America's Pharmaceuticals Act of 2013
Client: ENDO INTERNATIONAL · Firm: ENDO INTERNATIONAL
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
ENDO INTERNATIONAL via ENDO INTERNATIONAL
2013 · third_quarter · Q3
Issues relating to incentives for life sciences research H.R. 523/S. 232--Protect Medical Innovation Act of 2013
Oversight of implementation of the America Invents Act Issues relating to patent settlements Legislation relating to abusive patent litigation
Source: Senate LDA
Issues relating to bioequivalence and related administrative procedures Issues relating to prescription drug abuse Issues relating to incentives for tamper-resistant formulations H.R. 486--Stop Tampering of Prescription Pills Act of 2013Issues relating to Medicare Part D rebates Issues relating to health information technology H.R. 1919 -- Safeguarding America's Pharmaceuticals Act of 2013 H.R. 3204 -- Compounding and drug supply chain legislation H.R. 984 -- Urotrauma legislation U.S. Preventive Services Task Force recommendations on PSA testing for prostate cancer
Issues relating to bioequivalence and related administrative procedures Issues relating to prescription drug abuse Issues relating to incentives for tamper-resistant formulations H.R. 486--Stop Tampering of Prescription Pills Act of 2013Issues relating to Medicare Part D rebates Issues relating to health information technology H.R. 1919 -- Safeguarding America's Pharmaceuticals Act of 2013 H.R. 3204 -- Compounding and drug supply chain legislation H.R. 984 -- Urotrauma legislation U.S. Preventive Services Task Force recommendations on PSA testing for prostate cancer
Stop Tampering of Prescription Pills Act of 2013
Client: ENDO INTERNATIONAL · Firm: ENDO INTERNATIONAL
Issues relating to bioequivalence and related administrative procedures Issues relating to prescription drug abuse Issues relating to incentives for tamper-resistant formulations H.R. 486--Stop Tampering of Prescription Pills Act of 2013Issues relating to Medicare Part D rebates Issues relating to health information technology H.R. 1919 -- Safeguarding America's Pharmaceuticals Act of 2013
Stop Tampering of Prescription Pills Act of 2013
Client: ENDO INTERNATIONAL · Firm: ENDO INTERNATIONAL
Issues relating to bioequivalence and related administrative procedures Issues relating to prescription drug abuse Issues relating to incentives for tamper-resistant formulations H.R. 486--Stop Tampering of Prescription Pills Act of 2013Issues relating to Medicare Part D rebates Issues relating to health information technology
Stop Tampering of Prescription Pills Act of 2013
Client: ENDO INTERNATIONAL · Firm: ENDO INTERNATIONAL
Issues relating to bioequivalence and related administrative procedures Issues relating to prescription drug abuse Issues relating to incentives for tamper-resistant formulations H.R. 486--Stop Tampering of Prescription Pills Act of 2013Issues relating to Medicare Part D rebates Issues relating to health information technology H.R. 1919 -- Safeguarding America's Pharmaceuticals Act of 2013 H.R. 3204 -- Compounding and drug supply chain legislation H.R. 984 -- Urotrauma legislation U.S. Preventive Services Task Force recommendations on PSA testing for prostate cancer
Issues relating to incentives for life science research H.R. 523/S. 232--Protect Medical Innovation Act of 2013
Issues relating to incentives for life sciences research H.R. 523/S. 232--Protect Medical Innovation Act of 2013 Life Sciences Jobs and Investment Act
Issues relating to incentives for life sciences research H.R. 523/S. 232--Protect Medical Innovation Act of 2013
To direct the Secretary of Defense to establish a task force on urotrauma.
Client: ENDO INTERNATIONAL · Firm: ENDO INTERNATIONAL
Issues relating to bioequivalence and related administrative procedures Issues relating to prescription drug abuse Issues relating to incentives for tamper-resistant formulations H.R. 486--Stop Tampering of Prescription Pills Act of 2013Issues relating to Medicare Part D rebates Issues relating to health information technology H.R. 1919 -- Safeguarding America's Pharmaceuticals Act of 2013 H.R. 3204 -- Compounding and drug supply chain legislation H.R. 984 -- Urotrauma legislation U.S. Preventive Services Task Force recommendations on PSA testing for prostate cancer
Medical Device Access and Innovation Protection Act
Client: ENDO INTERNATIONAL · Firm: ENDO INTERNATIONAL
Issues relating to incentives for life sciences research H.R. 523/S. 232--Protect Medical Innovation Act of 2013
Medical Device Access and Innovation Protection Act
Client: ENDO INTERNATIONAL · Firm: ENDO INTERNATIONAL
Issues relating to incentives for life sciences research H.R. 523/S. 232--Protect Medical Innovation Act of 2013 Life Sciences Jobs and Investment Act
Medical Device Access and Innovation Protection Act
Client: ENDO INTERNATIONAL · Firm: ENDO INTERNATIONAL
Issues relating to incentives for life science research H.R. 523/S. 232--Protect Medical Innovation Act of 2013
Repealing the Job-Killing Health Care Law Act
Client: ENDO INTERNATIONAL · Firm: ENDO INTERNATIONAL
Drug reimportation issues (S. 319); Reauthorization of Prescription Drug User Fee Act; Life sciences research tax credit legislation (Life Sciences Jobs and Investment Act--H.R.2632, S. 1410); Healthcare reform bill repeal (H.R. 2); Preserving Access to Orphan Drus Act of 2011 (H.R. 2672, S. 1423); Medicare rebates and reimbursement rates; 340B drug discount program (340B Program Improvement Act--H.R. 2674); Generic Drug and Biosimilar User Fee Act of 2012 (H.R. 3998).
Life Sciences Jobs and Investment Act of 2011
Client: ENDO INTERNATIONAL · Firm: ENDO INTERNATIONAL
Life Sciences Jobs and Investment Act (H.R. 2632, S. 1410).
Life Sciences Jobs and Investment Act of 2011
Client: ENDO INTERNATIONAL · Firm: ENDO INTERNATIONAL
Drug reimportation issues (S. 319); Reauthorization of Prescription Drug User Fee Act; Life sciences research tax credit legislation (Life Sciences Jobs and Investment Act--H.R.2632, S. 1410); Healthcare reform bill repeal (H.R. 2); Preserving Access to Orphan Drus Act of 2011 (H.R. 2672, S. 1423); Medicare rebates and reimbursement rates; 340B drug discount program (340B Program Improvement Act--H.R. 2674); Generic Drug and Biosimilar User Fee Act of 2012 (H.R. 3998).
Life Sciences Jobs and Investment Act of 2011
Client: ENDO INTERNATIONAL · Firm: ENDO INTERNATIONAL
H.R. 2632, Life Sciences Jobs and Investment Act of 2011.
Life Sciences Jobs and Investment Act of 2011
Client: ENDO INTERNATIONAL · Firm: ENDO INTERNATIONAL
H.R. 2632, Life Sciences Jobs and Investment Act of 2011.
Life Sciences Jobs and Investment Act of 2011
Client: ENDO INTERNATIONAL · Firm: ENDO INTERNATIONAL
H.R. 2632, Life Sciences Jobs and Investment Act of 2011.
Preserving Access to Orphan Drugs Act of 2011
Client: ENDO INTERNATIONAL · Firm: ENDO INTERNATIONAL
Drug reimportation issues (S. 319); Reauthorization of Prescription Drug User Fee Act; Life sciences research tax credit legislation (Life Sciences Jobs and Investment Act--H.R.2632, S. 1410); Healthcare reform bill repeal (H.R. 2); Preserving Access to Orphan Drus Act of 2011 (H.R. 2672, S. 1423); Medicare rebates and reimbursement rates; 340B drug discount program (340B Program Improvement Act--H.R. 2674); Generic Drug and Biosimilar User Fee Act of 2012 (H.R. 3998).
Drug reimportation issues (S. 319); Reauthorization of Prescription Drug User Fee Act; Life sciences research tax credit legislation (Life Sciences Jobs and Investment Act--H.R.2632, S. 1410); Healthcare reform bill repeal (H.R. 2); Preserving Access to Orphan Drus Act of 2011 (H.R. 2672, S. 1423); Medicare rebates and reimbursement rates; 340B drug discount program (340B Program Improvement Act--H.R. 2674); Generic Drug and Biosimilar User Fee Act of 2012 (H.R. 3998).
H.R. 3010, Regulatory Accountability Act of 2011.
H.R. 3010, Regulatory Accountability Act of 2011.
H.R. 3010, Regulatory Accountability Act of 2011.
Generic Drug and Biosimilar User Fee Act of 2012
Client: ENDO INTERNATIONAL · Firm: ENDO INTERNATIONAL
S. 319, Pharmaceutical Market Access and Drug Safety Act of 2011 H.R. 3988, Generic Drug and Biosimilar User Fee Act of 2012 S. 3187, FDA Safety and Innovation Act H.R. 5998, USPSTF Transparency and Accountability Act H.R. 6544, Manufacturing Innovation in America Act H.R. 6160, Stop Tampering of Prescription Pills Act H.R. 436, Health Care Cost Reduction Act regarding medical device excise tax repeal Issues relating to bioequivalence and related administrative procedures Issues relating to DEA quotas for controlled substances Oversight of DEA Issues relating to prescription drug abuse Issues relating to incentives for tamper-resistant formulations
Generic Drug and Biosimilar User Fee Act of 2012
Client: ENDO INTERNATIONAL · Firm: ENDO INTERNATIONAL
S. 319, Pharmaceutical Market Access and Drug Safety Act of 2011; H.R. 3988, Generic Drug and Biosimilar User Fee Act of 2012; S. 3187, FDA Safety and Innovation Act; issues relating to bioequivalence and related administrative procedures; issues relating to DEA quotas for controlled substances; oversight of DEA; issues relating to prescription drug abuse.
Generic Drug and Biosimilar User Fee Act of 2012
Client: ENDO INTERNATIONAL · Firm: ENDO INTERNATIONAL
S. 319, Pharmaceutical Market Access and Drug Safety Act of 2011 H.R. 3988, Generic Drug and Biosimilar User Fee Act of 2012 S. 3187, FDA Safety and Innovation Act Issues relating to bioequivalence and related administrative procedures Issues relating to DEA quotas for controlled substances Oversight of DEA Issues relating to prescription drug abuse Issues relating to incentives for tamper-resistant formulations
To amend the Internal Revenue Code of 1986 to extend the deduction for certain expenses of elementary and secondary school teachers.
Client: ENDO INTERNATIONAL · Firm: ENDO INTERNATIONAL
Drug reimportation issues (S. 319); Reauthorization of Prescription Drug User Fee Act; Life sciences research tax credit legislation (Life Sciences Jobs and Investment Act--H.R.2632, S. 1410); Healthcare reform bill repeal (H.R. 2); Preserving Access to Orphan Drus Act of 2011 (H.R. 2672, S. 1423); Medicare rebates and reimbursement rates; 340B drug discount program (340B Program Improvement Act--H.R. 2674); Generic Drug and Biosimilar User Fee Act of 2012 (H.R. 3998).
S. 319, Pharmaceutical Market Access and Drug Safety Act of 2011 H.R. 3988, Generic Drug and Biosimilar User Fee Act of 2012 S. 3187, FDA Safety and Innovation Act H.R. 5998, USPSTF Transparency and Accountability Act H.R. 6544, Manufacturing Innovation in America Act H.R. 6160, Stop Tampering of Prescription Pills Act H.R. 436, Health Care Cost Reduction Act regarding medical device excise tax repeal Issues relating to bioequivalence and related administrative procedures Issues relating to DEA quotas for controlled substances Oversight of DEA Issues relating to prescription drug abuse Issues relating to incentives for tamper-resistant formulations
USPSTF Transparency and Accountability Act of 2012
Client: ENDO INTERNATIONAL · Firm: ENDO INTERNATIONAL
S. 319, Pharmaceutical Market Access and Drug Safety Act of 2011 H.R. 3988, Generic Drug and Biosimilar User Fee Act of 2012 S. 3187, FDA Safety and Innovation Act H.R. 5998, USPSTF Transparency and Accountability Act H.R. 6544, Manufacturing Innovation in America Act H.R. 6160, Stop Tampering of Prescription Pills Act H.R. 436, Health Care Cost Reduction Act regarding medical device excise tax repeal Issues relating to bioequivalence and related administrative procedures Issues relating to DEA quotas for controlled substances Oversight of DEA Issues relating to prescription drug abuse Issues relating to incentives for tamper-resistant formulations
Stop Tampering of Prescription Pills Act of 2012
Client: ENDO INTERNATIONAL · Firm: ENDO INTERNATIONAL
S. 319, Pharmaceutical Market Access and Drug Safety Act of 2011 H.R. 3988, Generic Drug and Biosimilar User Fee Act of 2012 S. 3187, FDA Safety and Innovation Act H.R. 5998, USPSTF Transparency and Accountability Act H.R. 6544, Manufacturing Innovation in America Act H.R. 6160, Stop Tampering of Prescription Pills Act H.R. 436, Health Care Cost Reduction Act regarding medical device excise tax repeal Issues relating to bioequivalence and related administrative procedures Issues relating to DEA quotas for controlled substances Oversight of DEA Issues relating to prescription drug abuse Issues relating to incentives for tamper-resistant formulations
Manufacturing Innovation in America Act of 2012
Client: ENDO INTERNATIONAL · Firm: ENDO INTERNATIONAL
S. 319, Pharmaceutical Market Access and Drug Safety Act of 2011 H.R. 3988, Generic Drug and Biosimilar User Fee Act of 2012 S. 3187, FDA Safety and Innovation Act H.R. 5998, USPSTF Transparency and Accountability Act H.R. 6544, Manufacturing Innovation in America Act H.R. 6160, Stop Tampering of Prescription Pills Act H.R. 436, Health Care Cost Reduction Act regarding medical device excise tax repeal Issues relating to bioequivalence and related administrative procedures Issues relating to DEA quotas for controlled substances Oversight of DEA Issues relating to prescription drug abuse Issues relating to incentives for tamper-resistant formulations
Repealing the Job-Killing Health Care Law Act
Client: ENDO INTERNATIONAL · Firm: ENDO INTERNATIONAL
Drug reimportation issues (S. 319); Reauthorization of Prescription Drug User Fee Act; Life sciences research tax credit legislation (Life Sciences Jobs and Investment Act--H.R.2632, S. 1410); Healthcare reform bill repeal (H.R. 2); Preserving Access to Orphan Drus Act of 2011 (H.R. 2672, S. 1423); Medicare rebates and reimbursement rates; 340B drug discount program (340B Program Improvement Act--H.R. 2674)
Life Sciences Jobs and Investment Act of 2011
Client: ENDO INTERNATIONAL · Firm: ENDO INTERNATIONAL
Life Sciences Jobs and Investment Act (H.R. 2632, S. 1410)
Life Sciences Jobs and Investment Act of 2011
Client: ENDO INTERNATIONAL · Firm: ENDO INTERNATIONAL
Drug reimportation issues (S. 319); Reauthorization of Prescription Drug User Fee Act; Life sciences research tax credit legislation (Life Sciences Jobs and Investment Act--H.R.2632, S. 1410); Healthcare reform bill repeal (H.R. 2); Preserving Access to Orphan Drus Act of 2011 (H.R. 2672, S. 1423); Medicare rebates and reimbursement rates; 340B drug discount program (340B Program Improvement Act--H.R. 2674)
Preserving Access to Orphan Drugs Act of 2011
Client: ENDO INTERNATIONAL · Firm: ENDO INTERNATIONAL
Drug reimportation issues (S. 319); Reauthorization of Prescription Drug User Fee Act; Life sciences research tax credit legislation (Life Sciences Jobs and Investment Act--H.R.2632, S. 1410); Healthcare reform bill repeal (H.R. 2); Preserving Access to Orphan Drus Act of 2011 (H.R. 2672, S. 1423); Medicare rebates and reimbursement rates; 340B drug discount program (340B Program Improvement Act--H.R. 2674)
Drug reimportation issues (S. 319); Reauthorization of Prescription Drug User Fee Act; Life sciences research tax credit legislation (Life Sciences Jobs and Investment Act--H.R.2632, S. 1410); Healthcare reform bill repeal (H.R. 2); Preserving Access to Orphan Drus Act of 2011 (H.R. 2672, S. 1423); Medicare rebates and reimbursement rates; 340B drug discount program (340B Program Improvement Act--H.R. 2674)
Issues relating to bioequivalence and related administrative procedures Issues relating to prescription drug abuse Issues relating to incentives for tamper-resistant formulations H.R. 486--Stop Tampering of Prescription Pills Act of 2013Issues relating to Medicare Part D rebates Issues relating to health information technology H.R. 1919 -- Safeguarding America's Pharmaceuticals Act of 2013 H.R. 3204 -- Compounding and drug supply chain legislation H.R. 984 -- Urotrauma legislation U.S. Preventive Services Task Force recommendations on PSA testing for prostate cancer
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ENDO INTERNATIONAL via ENDO INTERNATIONAL
2013 · second_quarter · Q2
Issues relating to bioequivalence and related administrative procedures Issues relating to prescription drug abuse Issues relating to incentives for tamper-resistant formulations H.R. 486--Stop Tampering of Prescription Pills Act of 2013Issues relating to Medicare Part D rebates Issues relating to health information technology H.R. 1919 -- Safeguarding America's Pharmaceuticals Act of 2013
Issues relating to incentives for life sciences research H.R. 523/S. 232--Protect Medical Innovation Act of 2013 Life Sciences Jobs and Investment Act
Oversight of implementation of the America Invents Act Issues relating to patent settlements Legislation relating to abusive patent litigation
Issues related to tamper resistant formulation of pharmaceutical drugs Life Sciences Jobs and Investment Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ENDO INTERNATIONAL via ENDO INTERNATIONAL
2013 · first_quarter · Q1
Issues relating to incentives for life science research H.R. 523/S. 232--Protect Medical Innovation Act of 2013
Oversight of implementation of the America Invents Act. Issues realting to patent settlements
Issues relating to bioequivalence and related administrative procedures Issues relating to prescription drug abuse Issues relating to incentives for tamper-resistant formulations H.R. 486--Stop Tampering of Prescription Pills Act of 2013Issues relating to Medicare Part D rebates Issues relating to health information technology
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ENDO INTERNATIONAL via ENDO INTERNATIONAL
2012 · fourth_quarter · Q4
Oversight of implementation of the America Invents Act.
S. 319, Pharmaceutical Market Access and Drug Safety Act of 2011 H.R. 3988, Generic Drug and Biosimilar User Fee Act of 2012 S. 3187, FDA Safety and Innovation Act Issues relating to bioequivalence and related administrative procedures Issues relating to DEA quotas for controlled substances Oversight of DEA Issues relating to prescription drug abuse Issues relating to incentives for tamper-resistant formulations
H.R. 3010, Regulatory Accountability Act of 2011.
H.R. 2632, Life Sciences Jobs and Investment Act of 2011.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ENDO INTERNATIONAL via ENDO INTERNATIONAL
2012 · third_quarter · Q3
H.R. 3010, Regulatory Accountability Act of 2011.
H.R. 2632, Life Sciences Jobs and Investment Act of 2011.
S. 319, Pharmaceutical Market Access and Drug Safety Act of 2011 H.R. 3988, Generic Drug and Biosimilar User Fee Act of 2012 S. 3187, FDA Safety and Innovation Act H.R. 5998, USPSTF Transparency and Accountability Act H.R. 6544, Manufacturing Innovation in America Act H.R. 6160, Stop Tampering of Prescription Pills Act H.R. 436, Health Care Cost Reduction Act regarding medical device excise tax repeal Issues relating to bioequivalence and related administrative procedures Issues relating to DEA quotas for controlled substances Oversight of DEA Issues relating to prescription drug abuse Issues relating to incentives for tamper-resistant formulations
Oversight of implementation of the America Invents Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ENDO INTERNATIONAL via ENDO INTERNATIONAL
2012 · second_quarter · Q2
H.R. 2632, Life Sciences Jobs and Investment Act of 2011.
S. 319, Pharmaceutical Market Access and Drug Safety Act of 2011; H.R. 3988, Generic Drug and Biosimilar User Fee Act of 2012; S. 3187, FDA Safety and Innovation Act; issues relating to bioequivalence and related administrative procedures; issues relating to DEA quotas for controlled substances; oversight of DEA; issues relating to prescription drug abuse.
Oversight of implementation of the America Invents Act.
ENDO INTERNATIONAL via ENDO INTERNATIONAL
2012 · first_quarter · Q1
Patent reform issues (H.R. 1249, S. 23); Pattent settlements (S. 27).
Drug reimportation issues (S. 319); Reauthorization of Prescription Drug User Fee Act; Life sciences research tax credit legislation (Life Sciences Jobs and Investment Act--H.R.2632, S. 1410); Healthcare reform bill repeal (H.R. 2); Preserving Access to Orphan Drus Act of 2011 (H.R. 2672, S. 1423); Medicare rebates and reimbursement rates; 340B drug discount program (340B Program Improvement Act--H.R. 2674); Generic Drug and Biosimilar User Fee Act of 2012 (H.R. 3998).
Life Sciences Jobs and Investment Act (H.R. 2632, S. 1410).
ENDO INTERNATIONAL via ENDO INTERNATIONAL
2011 · fourth_quarter · Q4
Patent reform issues (H.R. 1249, S. 23); Pattent settlements (S. 27).
Life Sciences Jobs and Investment Act (H.R. 2632, S. 1410)
Drug reimportation issues (S. 319); Reauthorization of Prescription Drug User Fee Act; Life sciences research tax credit legislation (Life Sciences Jobs and Investment Act--H.R.2632, S. 1410); Healthcare reform bill repeal (H.R. 2); Preserving Access to Orphan Drus Act of 2011 (H.R. 2672, S. 1423); Medicare rebates and reimbursement rates; 340B drug discount program (340B Program Improvement Act--H.R. 2674)
H.R. 3010, Regulatory Accountability Act of 2011.
Filing targets: Drug Enforcement Administration (DEA), HOUSE OF REPRESENTATIVES, SENATE
Filing targets: Drug Enforcement Administration (DEA), HOUSE OF REPRESENTATIVES, SENATE
Filing targets: Drug Enforcement Administration (DEA), HOUSE OF REPRESENTATIVES, SENATE